Targeting B-cell Maturation Antigen in Relapsed/Refractory Multiple Myeloma: New Findings in Clinical Context

Targeting B-cell Maturation Antigen in Relapsed/Refractory Multiple Myeloma: New Findings in Clinical Context
Targeting B-cell Maturation Antigen in Relapsed/Refractory Multiple Myeloma: New Findings in Clinical Context
CME, CPE, CNE
Robert Z. Orlowski, MD, PhD; Nikhil C. Munshi, MD; Nina Shah, MD
Release Date: October 07, 2019
Expiration Date: October 07, 2020

Awareness and knowledge of B-cell maturation antigen (BCMA) as a therapeutic target remains limited among clinicians who provide care for patients with relapsed/refractory multiple myeloma (MM). However, the number of clinical trials evaluating these therapies is rapidly increasing; and a few have even received breakthrough therapy status. In this activity, three myeloma experts discuss the most recent and up-to-date clinical trial information on this exciting topic. Hear what is to come in the near future and how these emerging agents will be positioned in the treatment of relapsed multiple myeloma.

This activity was previously presented on September 6, 2019 to a live audience during the ASH Meeting on Hematologic Malignancies in Chicago, Illinois. Please note: If you attended the live meeting or simulcast viewing, you are ineligible to receive an additional 2.0 contact hours of credit and may not re-submit for credit previously awarded.

Provided by The University of Texas MD Anderson Cancer Center and MediCom Worldwide, Inc.
This activity is supported by educational grants from Celgene Corporation and GlaxoSmithKline.

Begin, Earn CreditView Only, No Credit